ImageneBio (IMA)
NASDAQ:IMA
Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $18.01
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$60.51M
Enterprise Value-$6.88M
Total Cash (Recent Filing)$117.21M
Total Debt (Recent Filing)$8.15M
Price to Earnings (P/E)―
Beta0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,654,281
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap-0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.82
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$13.00Price Target Upside120.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt provides durable financial flexibility for a pre-commercial biotech: it lowers fixed financing costs and bankruptcy risk, enabling management to prioritize funding clinical programs and R&D rather than servicing debt, which supports sustained pipeline progress.
$30M Private Warrant FinancingThe ~$30M private warrant financing materially extends near-term cash runway and is earmarked for late-phase development and indication expansion for IMG-007. This structural capital infusion reduces immediate funding pressure and supports execution of clinical milestones.
Finance Leadership ContinuityPromotion of an experienced biotech finance executive provides continuity and stronger financial controls during active fundraising and clinical stages. Improved finance leadership helps manage complex financings, compliance and budgeting, lowering execution risk over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$52M TTM is a durable constraint: the company must repeatedly access capital markets to fund operations, which raises dilution risk and could delay or reduce pipeline investment if markets tighten.
Minimal Revenue / Ongoing LossesA pre-commercial profile with no material revenue and consistent multi‑year net losses means long reliance on milestone success to generate cash. Without a revenue base, valuation and financial resilience hinge entirely on clinical outcomes, increasing binary risk for investors and operations.
Dilution And Registration Obligations From FinancingWhile the financing supplies cash, pre-funded warrants create future dilution and binding registration obligations with penalty exposure. Large warrant overhang can alter capital structure, pressure future equity rounds, and impose operational/legal costs if registration timelines slip.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $18.01 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $60.51M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 10,654,281 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-35.20%
Trailing 12-Months
Asset Growth
4.47%
Trailing 12-Months
Company Description
ImageneBio
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
IMA Stock 12 Month Forecast
Average Price Target
$13.00
▲(120.34% Upside)
Technical Analysis
Ownership Overview
32.91% Insiders
2.77% Mutual Funds
42.06% Other Institutional Investors
19.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---